| A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Active, not recruiting | P3 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) NCT07247084 | Recruiting | P4 | Eli Lilly and Company |
| Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Recruiting | P3 | Hudson Biotech |
| A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight NCT04184622 | Completed | P3 | Eli Lilly and Company |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Recruiting | P2 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight NCT04657003 | Completed | P3 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Active, not recruiting | P3 | Eli Lilly and Company |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Active, not recruiting | P3 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss NCT04660643 | Completed | P3 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial NCT04847557 | Completed | P3 | Eli Lilly and Company |
| Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients NCT07715929 | Not yet recruiting | P4 | Yunlong Wang |
| A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program NCT04657016 | Completed | P3 | Eli Lilly and Company |
| Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea NCT05412004 | Completed | P3 | Eli Lilly and Company |
| A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Active, not recruiting | P3 | Eli Lilly and Company |
| A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities NCT06047548 | Completed | P3 | Eli Lilly and Company |
| Efficacy and Safety of Tirzepatide for Weight Management NCT06918405 | Active, not recruiting | P3 | Chittagong Medical College |
| A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity NCT06037252 | Active, not recruiting | P2 | Eli Lilly and Company |
| AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Not yet recruiting | P4 | Huazhong University of Science and Technology |
| A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity NCT06373146 | Completed | P2 | Eli Lilly and Company |
| Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Recruiting | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571 | Active, not recruiting | P2 | Eli Lilly and Company |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight NCT06326060 | Completed | P2 | Novo Nordisk A/S |
| Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) | Recruiting | P4 | University of Melbourne |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Recruiting | P3 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Active, not recruiting | P4 | Eli Lilly and Company |
| Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants NCT06737042 | Completed | P2 | Gan and Lee Pharmaceuticals, USA |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Recruiting | P3 | Eli Lilly and Company |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Recruiting | P3 | Eli Lilly and Company |
| A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity NCT06965413 | Active, not recruiting | P2 | Hoffmann-La Roche |
| AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | Not yet recruiting | P4 | The First Affiliated Hospital of Anhui Medical University |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight NCT06588283 | Completed | P3 | Eli Lilly and Company |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight NCT06588296 | Completed | P3 | Eli Lilly and Company |
| A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease NCT04844918 | Completed | P3 | Eli Lilly and Company |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728 | Active, not recruiting | P2 | Eli Lilly and Company |
| Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | Not yet recruiting | P2 | Biomed Industries, Inc. |
| A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) NCT05024032 | Completed | P3 | Eli Lilly and Company |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over NCT06515418 | Terminated | P2 | BioAge Labs, Inc. |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Recruiting | P4 | Eli Lilly and Company |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Recruiting | P4 | Eli Lilly and Company |
| A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Recruiting | P4 | University of Bonn |
| Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Recruiting | P4 | Las Rías Medical Center |
| A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities NCT06075667 | Active, not recruiting | P3 | Eli Lilly and Company |
| Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Not yet recruiting | P4 | Technical University of Munich |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes NCT05536804 | Active, not recruiting | P2 | Eli Lilly and Company |
| Glucagon-Like Peptide-1 Receptor Agonist in ADPKD NCT06582875 | Recruiting | P2 | University of Colorado, Denver |
| The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | Recruiting | P4 | Tina Vilsbøll |
| A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity NCT06565611 | Active, not recruiting | P2 | Palatin Technologies, Inc |
| Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Recruiting | P2 | Johns Hopkins University |
| Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese NCT06445075 | Completed | P2 | Scholar Rock, Inc. |
| TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | Recruiting | P2 | The Cleveland Clinic |
| A Study of BGM0504 in Participants With Obesity NCT06911203 | Recruiting | P2 | BrightGene Bio-Medical Technology Co., Ltd. |
| Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity NCT05912621 | Recruiting | P2 | Stanford University |
| Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity NCT05933499 | Recruiting | P2 | Massachusetts General Hospital |
| A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants NCT07671391 | Not yet recruiting | P2 | Shanghai Zhongshan Hospital |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV NCT07707778 | Enrolling by invitation | P4 | National Taiwan University Clinical Trial Center |
| Tirzepatide Use in People With Obesity and Type 1 Diabetes NCT07096908 | Recruiting | P4 | Dasman Diabetes Institute |
| Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity NCT07738276 | Not yet recruiting | P3 | Shahid Beheshti University of Medical Sciences |
| GLP-1R Actions on Muscle and the Skeleton | Recruiting | P4 | Pennington Biomedical Research Center |
| Incretin Therapies in Obesity-related HFpEF | Recruiting | P4 | Columbia University |
| 2024 Tirzepatide-Bariatric Surgery NCT06721507 | Recruiting | P4 | Marlene Starr |